Search for Clinical Trial Results
Microsatellite Instability - 23 Studies Found
Status | Study |
Not yet recruiting |
Study Name: Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer Condition:
|
Completed |
Study Name: Molecular Biology of Anal Cancer in HIV-Positive Patients Condition:
Date: 2009-08-03 |
Active, not recruiting |
Study Name: Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164) Condition: Colorectal Carcinoma Date: 2015-05-29 Interventions: Biological: Pembrolizumab IV infusion Other Names: |
Not yet recruiting |
Study Name: Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types Condition:
|
Recruiting |
Study Name: A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (INCB 24360-202 / MK-3475-037 / KEYNOTE-037/ ECHO-202) Condition:
|
Recruiting |
Study Name: Clinical and Molecular Characterization of Familial Microsatellite Stable Colorectal Cancer Condition: Colorectal Neoplasms Date: 2005-09-20 |
Recruiting |
Study Name: Implementation of a New Strategy to Identify HNPCC Patients Condition:
Date: 2005-08-31 Interventions:
|
Not yet recruiting |
Study Name: Diagnosis of Lynch Syndrome Based on Next-generation Sequencing in Colorectal Cancer Condition: Lynch Syndrome Date: 2017-01-23 Interventions: Other: next-generation sequencing Use next-generation sequencing to test germline mutation and microsate |
Not yet recruiting |
Study Name: Postoperative Radiotherapy According to Molecular Analysis of Surgical Margins of Oral and Oropharyngeal SCC Condition:
Date: 2005-10-04 Interventions: Procedure: Radiotherapy 50 Gy |
Recruiting |
Study Name: Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Condition: Advanced Cancer Date: 2015-12-09 Interventions: Biological: pembrolizumab intravenous infusion Other |